Continuing its buying spree, AbbVie has agreed to acquire Cerevel Therapeutics for US$45 per share in cash, representing a total equity value of approximately US$8.7 B. Through the takeover, AbbVie gains access to a pipeline of assets focused on the treatment of psychiatric and neurological disorders including Phase II asset, emraclidine, for schizophrenia. The deal comes one week after AbbVie agreed to acquire antibody-drug conjugate developer ImmunoGen for US$10.1 B, as the big pharma prepares for its post-Humira future.